Valeant Pharmaceuticals International Inc.'s (VRX)(VRX.TO) wholly owned subsidiary Bausch + Lomb has sought FDA approval for Luminesse, and the regulatory agency’s decision will be known on December 27, 2017.Luminesse, whose active ingredient is brimonidine tartrate, is proposed to be used Over-the-Counter (OTC) as an eye drop to relieve redness of the eye due to minor eye irritations. If approved, Luminesse will be the first OTC product developed with brimonidine tartrate for the treatment of ocular redness. Luminesse was licensed by privately held Eye Therapies Inc. to Bausch + Lomb.VRX closed Tuesday’s (Nov.28) trading at $16.40, down 0.49%.